Hypera S.A (HYPE3) - Total Assets
Based on the latest financial reports, Hypera S.A (HYPE3) holds total assets worth R$28.53 Billion BRL (≈ $5.60 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See HYPE3 book value for net asset value and shareholders' equity analysis.
Hypera S.A - Total Assets Trend (2005–2024)
This chart illustrates how Hypera S.A's total assets have evolved over time, based on quarterly financial data.
Hypera S.A - Asset Composition Analysis
Current Asset Composition (December 2024)
Hypera S.A's total assets of R$28.53 Billion consist of 27.2% current assets and 72.8% non-current assets.
| Asset Category | Amount (BRL) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | R$1.68 Billion | 7.1% |
| Accounts Receivable | R$2.25 Billion | 9.2% |
| Inventory | R$1.94 Billion | 7.9% |
| Property, Plant & Equipment | R$3.90 Billion | 15.9% |
| Intangible Assets | R$4.45 Billion | 18.1% |
| Goodwill | R$7.34 Billion | 29.9% |
Asset Composition Trend (2005–2024)
This chart illustrates how Hypera S.A's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see how much is Hypera S.A worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hypera S.A's current assets represent 27.2% of total assets in 2024, a decrease from 45.9% in 2005.
- Cash Position: Cash and equivalents constituted 7.1% of total assets in 2024, up from 0.2% in 2005.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 47.0% of total assets, a decrease from 53.0% in 2005.
- Asset Diversification: The largest asset category is goodwill at 29.9% of total assets.
Hypera S.A Competitors by Total Assets
Key competitors of Hypera S.A based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755
|
China | CN¥4.44 Billion |
|
Zhejiang Jiuzhou Pharm Co Ltd
SHG:603456
|
China | CN¥10.96 Billion |
|
Beijing Winsunny Pharmaceutical CO.LTD
SHG:601089
|
China | CN¥4.69 Billion |
|
KPC Pharmaceuticals Inc
SHG:600422
|
China | CN¥12.01 Billion |
|
Cronos Group Inc
TO:CRON
|
Canada | CA$1.18 Billion |
|
Cheng Du Sheng Nuo Biotec Co. Ltd. A
SHG:688117
|
China | CN¥1.91 Billion |
|
Jiangsu Jibeier Pharmaceutical Co Ltd
SHG:688566
|
China | CN¥2.64 Billion |
Hypera S.A - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.27 | 1.81 | 3.01 |
| Quick Ratio | 0.84 | 1.41 | 2.66 |
| Cash Ratio | 0.37 | 0.65 | 0.00 |
| Working Capital | R$1.33 Billion | R$3.94 Billion | R$5.28 Billion |
Hypera S.A - Advanced Valuation Insights
This section examines the relationship between Hypera S.A's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.15 |
| Latest Market Cap to Assets Ratio | 0.12 |
| Asset Growth Rate (YoY) | 0.2% |
| Total Assets | R$24.56 Billion |
| Market Capitalization | $2.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Hypera S.A's assets below their book value (0.12x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Hypera S.A's assets grew by 0.2% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Hypera S.A (2005–2024)
The table below shows the annual total assets of Hypera S.A from 2005 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | R$24.56 Billion ≈ $4.82 Billion |
+0.21% |
| 2023-12-31 | R$24.51 Billion ≈ $4.81 Billion |
+3.17% |
| 2022-12-31 | R$23.76 Billion ≈ $4.66 Billion |
+19.87% |
| 2021-12-31 | R$19.82 Billion ≈ $3.89 Billion |
+14.89% |
| 2020-12-31 | R$17.25 Billion ≈ $3.38 Billion |
+44.72% |
| 2019-12-31 | R$11.92 Billion ≈ $2.34 Billion |
+12.91% |
| 2018-12-31 | R$10.56 Billion ≈ $2.07 Billion |
+4.21% |
| 2017-12-31 | R$10.13 Billion ≈ $1.99 Billion |
-11.01% |
| 2016-12-31 | R$11.38 Billion ≈ $2.23 Billion |
-28.06% |
| 2015-12-31 | R$15.82 Billion ≈ $3.10 Billion |
+13.94% |
| 2014-12-31 | R$13.89 Billion ≈ $2.73 Billion |
+11.08% |
| 2013-12-31 | R$12.50 Billion ≈ $2.45 Billion |
-1.22% |
| 2012-12-31 | R$12.66 Billion ≈ $2.48 Billion |
-5.02% |
| 2011-12-31 | R$13.33 Billion ≈ $2.61 Billion |
+33.42% |
| 2010-12-31 | R$9.99 Billion ≈ $1.96 Billion |
+63.89% |
| 2009-12-31 | R$6.09 Billion ≈ $1.20 Billion |
+70.91% |
| 2008-12-31 | R$3.57 Billion ≈ $699.59 Million |
+80.93% |
| 2007-12-31 | R$1.97 Billion ≈ $386.66 Million |
+517.30% |
| 2006-12-31 | R$319.23 Million ≈ $62.64 Million |
+23.92% |
| 2005-12-31 | R$257.60 Million ≈ $50.55 Million |
-- |
About Hypera S.A
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, pleased, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid, Digedrat, diprogent, Diprosalic, Diprosone, diprospan, Emprol XR, Flow, Garasone, Halobex, Lipanon, Luna, moon, Lydian, macrodantin, MaxSulid, Milgamm… Read more